Featured Story | By Ben Adams Merck will no longer be able to supply an experimental COVID drug from its $425 million buyout of OncoImmune to the U.S. government under a $356 million contract as the FDA has demanded more data, delaying its supply. read more |
| |
|---|
|
Top Stories By Ben Adams Gossamer Bio has been unraveling over the past year, hit hard by a failure for its leading drug program and the axing of its CEO Sheila Gujrathi soon after. read more By Nick Paul Taylor Artiva Biotherapeutics has raised $120 million to advance a pipeline of allogeneic natural killer (NK) cell therapies. The Merck-partnered biotech has an unmodified NK cell therapy in the clinic and a clutch of CAR-engineered candidates following close behind. read more In Partnership With: AmerisourceBergen The Canadian pharmaceutical market, which is among the 10 largest worldwide, has long been viewed as a top-tier launch destination. read more By Amirah Al Idrus Foresite Capital banked $969 million in its fifth and biggest raise yet to invest in companies solving some of the biggest inefficiencies in today’s healthcare system. The capital will be split into two funds: About $775 million, or 80%, will go into a core fund, while the remaining $194 million will become what the firm calls an opportunity fund. read more By Nick Paul Taylor Genentech has partnered with the University of California (UC), San Francisco and UC Berkeley to work on neuroscience drugs. The Roche subsidiary has committed up to $53 million to collaborate with the academics on areas such as neurodegeneration over the next 10 years. read more By Conor Hale After launching a digital health collaboration two years ago, Otsuka and Click Therapeutics are now kicking off a fully remote clinical trial to evaluate an app meant to treat adults with major depressive disorder. read more By Arlene Weintraub Although acute myeloid leukemia (AML) is treatable with chemotherapy, patients often become resistant to it. Researchers at King’s College in London discovered that Merck’s drug Dificid, which inhibits the protein ABCC3, sensitized AML to treatment with doxorubicin and improved survival in mice. read more By Angus Liu Daiichi Sankyo poached Kite Pharma's research lead to be its own. China's Clover Biopharma hauled in a $230 million series C amid its COVID-19 vaccine work. Insilico Medicine made several breakthroughs with artificial intelligence in drug discovery. And more. read more By Fraiser Kansteiner Moderna's CMO is hitting the exit amid the biotech's COVID shot rollout. Novellus has completed its transformation into Fore Biotherapeutics, snagging a new CEO in the process. And Kite's research lead Takeshita has jumped ship to Daiichi Sankyo. read more Enrollment Showcase | Sponsored by: University of Florida College of Pharmacy Learn about the Top 5-Ranked UF College of Pharmacy’s online graduate programs in pharmaceutical outcomes & policy. Select from five specializations, including the new pharmaceutical value assessment & communication option. Over half of graduates progress to a new role within one year. Register now. |
| |
|---|
|
Resources Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored By: Within3 We enable virtual work — offering over-time sessions where participants are more focused, insights are more diverse and business goals are met. Sponsored By: Medidata, a Dassault Systèmes company 8 parameters to optimize your “Path to Virtualization” across site- and patient-centric capabilities in this Sponsor Edition eBook. Sponsored By: LabVantage Solutions Uncover the real impact of “digital transformation” with practical advice to help you plan your own transformative journey to a harmonized digital ecosystem. Sponsored By: Acorn AI, a Medidata Company Acorn AI has developed a flexible and scalable Commercial Data Model that provides pharmaceutical companies with the data-driven insights required to respond to the industry’s ever-changing landscape. Download the whitepaper to learn how Acorn AI’s intuitive data model enables launch success and more. Sponsored By: Outer Edge Technology Criminals Are Actively Exploiting The CV-19 Pandemic To Gain Entry To Enterprise Networks. Don’t Let Your Company Become A Cybercrime Statistic -- Make These Cost-Effective IT Changes Now! Sponsored by: Cytiva It’s an exciting time to pioneer what could be a life-changing medicine. Clear the path to the clinic with pro tips and expert insights from industry leaders. Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule Sponsored by: Catalent Autologous cell therapies have seen propelled growth since 2017, with the spotlight on the first FDA approval of a chimeric antigen receptor (CAR) T cell immunotherapy, Kymriah® (tisagenlecleucel), for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia. Sponsored by: Premier Research Browse the latest learnings and insights from our clinical development professionals. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. | 
